$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000140191422000051 Filed on May 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$10.00M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.818M	$2.595M	$2.427M
YoY Change	54.6%	31.73%	34.81%
% of Gross Profit
Research & Development	$6.798M	$5.805M	$7.116M
YoY Change	-7.39%	1.35%	7.18%
% of Gross Profit
Depreciation & Amortization	$5.320K	$5.227K	$7.040K
YoY Change	76.16%	-18.46%
% of Gross Profit
Operating Expenses	$9.616M	$8.400M	$9.543M
YoY Change	4.94%	9.19%	13.07%
Operating Profit	$384.3K	-$8.400M
YoY Change	-104.19%	9.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$29.68K	$1.779K	$830.00
YoY Change	16860.0%	59200.0%
Pretax Income	$414.0K	-$8.399M	-$9.542M
YoY Change	-104.52%	14.74%	13.06%
Income Tax
% Of Pretax Income
Net Earnings	$414.0K	-$8.400M	-$9.542M
YoY Change	-104.52%	14.7%	13.06%
Net Earnings / Revenue	4.14%
Basic Earnings Per Share	$0.00	-$0.10
Diluted Earnings Per Share	$4.850K	-$0.10	-$183.4K
COMMON SHARES
Basic Shares Outstanding	84.71M shares	83.94M shares	76.60M shares
Diluted Shares Outstanding	85.37M shares	83.94M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.07M	$39.32M	$51.67M
YoY Change	251.97%	413.28%	1006.51%
Cash & Equivalents	$32.07M	$39.32M	$51.67M
Short-Term Investments
Other Short-Term Assets	$5.904M	$6.770M	$2.477M
YoY Change	196.4%	312.83%	33.87%
Inventory
Prepaid Expenses		$6.770M	$2.477M
Receivables	$10.00M
Other Receivables	$2.138M	$1.730M	$1.145M
Total Short-Term Assets	$50.11M	$47.82M	$55.30M
YoY Change	256.44%	398.14%	691.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.121M	$25.37K	$26.04K
YoY Change	4400.18%	-19.52%	-31.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.9K	$1.344M	$485.1K
YoY Change	-78.21%	51.38%	-8.27%
Total Long-Term Assets	$1.282M	$1.369M	$511.2K
YoY Change	67.94%	48.95%	-9.82%
TOTAL ASSETS
Total Short-Term Assets	$50.11M	$47.82M	$55.30M
Total Long-Term Assets	$1.282M	$1.369M	$511.2K
Total Assets	$51.39M	$49.19M	$55.81M
YoY Change	246.73%	367.62%	639.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.114M	$2.831M	$2.103M
YoY Change	415.74%	92.36%	105.92%
Accrued Expenses	$6.671M	$3.538M	$3.136M
YoY Change	52.67%	40.4%	-6.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.54M	$16.39M	$16.05M
YoY Change	175.39%	168.39%	109.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.824M	$1.913M	$0.00
YoY Change	69.9%	66.36%	-100.0%
Total Long-Term Liabilities	$1.824M	$1.913M	$0.00
YoY Change	69.9%	66.36%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.54M	$16.39M	$16.05M
Total Long-Term Liabilities	$1.824M	$1.913M	$0.00
Total Liabilities	$18.36M	$18.31M	$17.05M
YoY Change	159.39%	152.16%	95.95%
SHAREHOLDERS EQUITY
Retained Earnings		-$118.5M	-$110.1M
YoY Change		50.38%	54.17%
Common Stock		$149.6M	$149.0M
YoY Change		82.15%	111.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.03M	$30.88M	$38.75M
YoY Change
Total Liabilities & Shareholders Equity	$51.39M	$49.19M	$55.81M
YoY Change	246.73%	367.62%	639.1%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	$414.0K	-$8.400M	-$9.542M
YoY Change	-104.52%	14.7%	13.06%
Depreciation, Depletion And Amortization	$5.320K	$5.227K	$7.040K
YoY Change	76.16%	-18.46%
Cash From Operating Activities	-$8.449M	-$12.34M	-$9.916M
YoY Change	-28.33%	47.35%	7.9%
INVESTING ACTIVITIES
Capital Expenditures	-$820.00	$4.553K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$820.00	-$4.553K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.339M	$0.00	16.00M
YoY Change	-89.9%	-100.0%	89.39%
NET CHANGE
Cash From Operating Activities	-8.449M	-$12.34M	-9.916M
Cash From Investing Activities	-820.0	-$4.553K	0.000
Cash From Financing Activities	1.339M	$0.00	16.00M
Net Change In Cash	-7.110M	-$12.36M	6.088M
YoY Change	-584.37%	-513.19%	-922.69%
FREE CASH FLOW
Cash From Operating Activities	-$8.449M	-$12.34M	-$9.916M
Capital Expenditures	-$820.00	$4.553K	$0.00
Free Cash Flow	-$8.448M	-$12.35M	-$9.916M
YoY Change	-28.34%	47.4%	7.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36395
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	DARÉ BIOSCIENCE, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4139823
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3655 Nobel Drive
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	926-7655
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q1	dei	Trading Symbol TradingSymbol	DARE
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	84711346	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39316911	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51674087	USD
CY2022Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1729851	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1145317	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6770426	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2476612	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	47817188	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	55296016	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25366	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26041	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1344028	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	485120	USD
CY2022Q1	us-gaap	Assets Assets	49186582	USD
CY2021Q4	us-gaap	Assets Assets	55807177	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2830866	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2103083	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3537856	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3136244	USD
CY2022Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	9731363	USD
CY2021Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	10542983	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	294474	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	270546	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16394559	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16052856	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	913113	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Liabilities Liabilities	18307672	USD
CY2021Q4	us-gaap	Liabilities Liabilities	17052856	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83944119	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83944119	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83944119	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83944119	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	8394	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8394	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-164123	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-154973	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	149560211	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	149027802	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118525572	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110126902	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30878910	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38754321	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49186582	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55807177	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2569987	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1940328	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5805462	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5728206	USD
CY2022Q1	dare	License Fee LicenseFee	25000	USD
CY2021Q1	dare	License Fee LicenseFee	25000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8400449	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	7693534	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8400449	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7693534	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1779	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	369887	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7323644	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6841	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8407820	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7330485	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83944119	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83944119	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44502582	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44502582	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38754321	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532409	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30878910	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1151733	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	365911	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11324140	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	50400	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7323644	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6841	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3258233	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7323644	USD
CY2022Q1	us-gaap	Depreciation Depreciation	5227	USD
CY2021Q1	us-gaap	Depreciation Depreciation	6410	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	532409	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	365911	USD
CY2022Q1	dare	Non Cash Lease Expense NonCashLeaseExpense	-9758	USD
CY2021Q1	dare	Non Cash Lease Expense NonCashLeaseExpense	-24224	USD
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	369887	USD
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	584534	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-158333	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4293814	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-217188	USD
CY2022Q1	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	-87891	USD
CY2021Q1	dare	Increase Decrease In Other Non Current Assets And Deferred Charges IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges	128086	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	727783	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	450298	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	401613	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-837191	USD
CY2022Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	811620	USD
CY2021Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	892123	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12343473	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8377015	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4553	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4553	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2022Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2021Q1	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	11324140	USD
CY2022Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2021Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	50400	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11374540	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9150	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6841	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12357176	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2990684	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51674087	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4669467	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39316911	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7660151	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8400000	USD
CY2022Q1	dare	Forgiveness Of Paycheck Protection Program Note Payable ForgivenessOfPaycheckProtectionProgramNotePayable	0	USD
CY2021Q1	dare	Forgiveness Of Paycheck Protection Program Note Payable ForgivenessOfPaycheckProtectionProgramNotePayable	369887	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1043590	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	308533	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118500000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39300000	USD
CY2022Q1	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	31400000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	12300000	USD
CY2022Q1	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27000000	shares
CY2021Q2	dare	Percentage Of Aggregate Commission PercentageOfAggregateCommission	0.03
CY2021Q2	dare	Percentage Of Aggregate Commission PercentageOfAggregateCommission	0.03
CY2018Q1	dare	Percentage Of Aggregate Commission PercentageOfAggregateCommission	0.030
CY2021Q4	dare	Deferred Offering Costs Unamortized Portion DeferredOfferingCostsUnamortizedPortion	0	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.96
CY2019Q2	dare	Deemed Dividend From Trigger Of Round Down Provision Feature DeemedDividendFromTriggerOfRoundDownProvisionFeature	800000	USD
CY2020Q3	dare	Deemed Dividend From Trigger Of Round Down Provision Feature DeemedDividendFromTriggerOfRoundDownProvisionFeature	6863	USD
CY2022Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2021Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	52500	shares
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	50000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1381015	shares
CY2022Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	5300000	USD
CY2022Q1	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y11M23D
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	913000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.22
CY2022Q1	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.38
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.07
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	294000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	169000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	135000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	123000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	112000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M17D
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	288000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	422000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	384000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	297000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1391000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	183000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1208000	USD
CY2022Q1	dare	Payment Of Additional Consideration In Business Combination PaymentOfAdditionalConsiderationInBusinessCombination	46500000	USD
CY2020Q2	dare	Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived	367285	USD
CY2021Q1	dare	Notes Payable Current Plus Accrued Interest NotesPayableCurrentPlusAccruedInterest	369887	USD
CY2018	dare	Proceeds From Award Of Grant ProceedsFromAwardOfGrant	1900000	USD
CY2021Q3	dare	Proceeds From Award Of Grant ProceedsFromAwardOfGrant	11450000	USD
CY2022Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	9700000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7658297	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6167434	shares

Files In Submission

Name	View Source	Status
0001401914-22-000051-index-headers.html	Edgar Link	pending
0001401914-22-000051-index.html	Edgar Link	pending
0001401914-22-000051.txt	Edgar Link	pending
0001401914-22-000051-xbrl.zip	Edgar Link	pending
dare-20220331.htm	Edgar Link	pending
dare-20220331.xsd	Edgar Link	pending
dare-20220331_cal.xml	Edgar Link	unprocessable
dare-20220331_def.xml	Edgar Link	unprocessable
dare-20220331_g1.jpg	Edgar Link	pending
dare-20220331_htm.xml	Edgar Link	completed
dare-20220331_lab.xml	Edgar Link	unprocessable
dare-20220331_pre.xml	Edgar Link	unprocessable
ex101_10q033122.htm	Edgar Link	pending
ex102_10q033122.htm	Edgar Link	pending
exhibit311_20220331.htm	Edgar Link	pending
exhibit312_20220331.htm	Edgar Link	pending
exhibit321_20220331.htm	Edgar Link	pending
exhibit322_20220331.htm	Edgar Link	pending
ex_102noneedirectorcomppol.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2022 Q2 Form 10-Q Financial Statement

#000140191422000051 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2022 Q2 Form 10-Q Financial Statement

#000140191422000051 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare